Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
B90 Holdings 5.75p £16.2m (B90.L)
The online marketing and service provision company for the gaming industry announces that it has raised £2.0m through a placing and subscription at a price of 5.44p per share, a 10% discount to a 5-day volume weighted average price as at close of business on 12 September 2023. The gross proceeds will be used as follows: £1.1m for inorganic growth opportunities; £0.4m for investment in B90's own assets and £0.5m for working capital and fundraising expenses. Concurrently, the Company has served conversion notices to all the holders of its convertible loan note (Loan Notes), pursuant to which £4,546,352 Loan Notes, together with £180,398 of accrued interest shall be converted at 5.44p per share. Following this conversion, no Loan Notes shall remain in issue.
Eagle Eye Solutions 542.p £158.7m (EYE.L)
The SaaS technology company that creates digital connections enabling personalised, real-time marketing announces that Malcolm Wall, Chair of the Board, will not seek re-election at the Company's forthcoming AGM in November 2023, as he has reached his nine-year tenure on the Board. The Company confirms that Anne de Kerckhove will join the Board on 1 October 2023 as Non-Executive Director and will succeed Malcolm as Chair at the conclusion of the AGM. Anne has held several senior Executive roles, including Global Director of Reed Elsevier and COO and International Managing Director at Inspired Gaming Group. Anne currently holds the position of Senior Independent Director of 888 Holdings plc and was previously Non-Executive Director at 7Digital Group plc.
Empyrean Energy 0.85p £8.3m (EME.L)
The oil and gas development company with interests in China, Indonesia and the United States, advises that it has issued new Ordinary Shares (Salary Sacrifice Shares) at a deemed price of 0.8p per share. The Salary Sacrifice Shares were issued in lieu of cash remuneration for the period June through to August 2023 in order to preserve capital and ensure more funds are directed towards project activities. This arrangement will conclude on the earlier of 31 December 2023 or the signing of a binding agreement for the sale (in part or whole) of Empyrean's interest in Mako.
GCM Resources 1.9p £3.9m (GCM.L)
The mining and energy company announces that for personal reasons Mohd Najib Bin Abdul Aziz has tendered his resignation from his position as Independent Non-Executive Chairman. Najib's resignation takes effect from 11 October 2023. Independent Non-Executive Director, Christian Taylor-Wilkinson has agreed to act as interim Non-Executive Chairman until the board makes its final decision on the Chairman role. The Company also announces that throughout the Bangladesh General Election period (election due in January 2024) it continues to promote its planned coal mining and power project in Bangladesh, which it aims to develop in partnership with the Government of Bangladesh.
One Heritage Group* 22.5p £8.7m (OHG.L)
The UK-based residential developer, development manager and property manager focused on the North of England provides an update on the sale of 15 units at Lincoln House, Bolton. The Company announced on 24 August 2023 that it was experiencing delays with the completion of the sale. On the 1 September 2023 a further announcement was made that legal notices to the buyer have been issued to complete the transaction within ten working days and that a further update will be provided by 15 September 2023. Notices to complete expired at the business close on 14 September 2023 and the Company expects to enter into an agreement with the buyer to allow an extension of time of 21 days for ten units once a further five sales are completed by close of business on 18 September 2023.
Primorus Investments 2.9p £4.1m (PRIM.L)
The investment company focused on the small and mid cap markets announces that the Company has invested an additional £75,000 into Interpac Ltd. Interpac was founded in 2013 to create a new corrugation process for the manufacture of cardboard in a cost-efficient and environmentally friendly way. Following this investment, Primorus holds approximately 4.29% of Interpac's issued share capital. Meanwhile, further to the announcement on 14 July 2023 regarding the convertible loan note the Company holds in Bushveld Minerals Limited, the Company has to date received approximately £505,000 under the repayment schedule with the outstanding balance expected to be repaid as per the terms of the announcement on 14 July 2023.
Rockfire Resources trading suspended (ROCK.L)
The gold, base metal and critical mineral exploration company announces the execution of a conditional share purchase agreement with Paloma Precious DMCC (Paloma) for the acquisition of 100% of Emirates Gold DMCC (Emirates) and 99% of Emperesse Bullion LLC (Emperesse) for a total consideration of USD$20m. Paloma is the largest shareholder in Rockfire, with an interest of 21.7% in the Company's issued share capital, and owns Emirates (100%) and Emperesse (99%). As part of the transaction, Rockfire will undertake a fundraise of approximately £14.7m at a price of 0.5p per share. On signing of the agreement, Rockfire will acquire 10% of Emirates and 10% of Emperesse (Initial Shares) for a consideration of US$2m. Rockfire is proposing to raise £3.5m from two new institutional investors at 0.5p per share.
SkinBioTherapeutics 22.75p £39.4m (SBTX.L)
The life science business focused on skin health announces that it has received approval from regulators for the French market for AxisBiotix-Ps™, a food supplement to alleviate the symptoms associated with psoriasis. Marketing is expected to launch in France in October. The announcement follows the launch of AxisBiotix-Ps in Spain and Italy earlier this year. Building on the initial launch in the UK where customer retention rates have remained above 80%, the launch of AxisBiotix-Ps into another European market is the continuation of this commercialisation strategy. The Company is in talks with other European regulatory agencies to expand the availability of AxisBiotix-Ps.
Webis Holdings 1.35p £5.3m (WEB.L)
The global gaming group announces that it has agreed to issue £1,150,000 of convertible loan notes to Galloway Limited, in respect of £750,000 of new funding made available to the Company by Galloway and in satisfaction of amounts due to Galloway pursuant to a prior loan made to the Company in 2017 which is due for repayment. The Convertible Notes comprise of £750,000 in respect of new funds advanced to the Company and an existing debt of £400,000 (after conversion of US$500,000 due and outstanding by the Company to Galloway). The Convertible Notes shall accrue interest at the rate of 11% per annum.
Quartix Technologies 210p £101.6m (QTX.L)
The supplier of subscription-based vehicle tracking systems, analytical software and services announces that acquisition of Konetik Deutschland GmbH (Konetik) the owner and developer of the software utilised in Quartix's EVolve electric vehicle product has now completed. Konetik has operations in Berlin and Budapest. The total consideration payable is EUR3.9m, all payable in cash, comprising an initial payment of EUR2.5m, payable immediately on completion and deferred consideration of up to EUR1.4m. Deferred consideration payable will be based on the number of EVolve subscriptions over the next 24 months. On account of the consideration being satisfied from the Company's existing cash reserves, the board expects a reduction in the FY23 supplemental dividend payable to shareholders. There will be no change to the ordinary dividend or the Company's dividend policy going forward.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
